Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
701-720 of 1,738 trials

Acetyl-L-Carnitine for ALS Treatment

We are studying whether acetyl-L-carnitine can help slow down the progression of ALS and improve quality of life. Participants will receive different doses to see which is most effective and safe.

Amyotrophic Lateral Sclerosis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesNeurology

Diffuse Large B-cell Lymphoma: Loncastuximab and Epcoritamab Study

We are studying a combination of two medications for patients with relapsed or refractory diffuse large B-cell lymphoma. The goal is to see how well this treatment works and its safety compared to existing options.

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL) Grade 3BHigh-Grade B-Cell Lymphoma (HGBL)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

DOK7 Congenital Myasthenic Syndrome: ARGX-119 Study

We are investigating the safety and tolerability of a new treatment, ARGX-119, for adults with DOK7 Congenital Myasthenic Syndrome. This study aims to understand how well the treatment is tolerated in this specific group.

Congenital Myasthenic Syndrome1-2 yearsSafety phase (I)Efficacy phase (II)Internal MedicineNeurology

Refractory Generalized Myasthenia Gravis: KYV-101 Therapy

We are studying a new CAR T-cell therapy for individuals with refractory generalized myasthenia gravis. The goal is to evaluate its safety and effectiveness in improving muscle strength.

Myasthenia GravisRefractory Generalized Myasthenia Gravis>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInfectious DiseasesNeurology

Mantle Cell Lymphoma: Zanubrutinib with Rituximab

We are comparing a new treatment combining Zanubrutinib and Rituximab to standard therapy for patients with untreated mantle cell lymphoma who cannot have a stem cell transplant. The goal is to see which treatment works better and is safer.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Difelikefalin for Itching in Adolescents on Hemodialysis

We are studying whether difelikefalin is safe for adolescents aged 12 to 17 who have moderate-to-severe itching related to long-term kidney disease. This trial aims to help improve care for young patients undergoing hemodialysis.

Generalized ItchingChronic Kidney Diseases3-6 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteDermatologyNephrologyPediatrics

Kidney Transplant: BIVV020 for Rejection Prevention and Treatment

We are studying BIVV020 to see if it can help prevent or treat antibody-mediated rejection in adults who have received a kidney transplant. This trial will assess its safety and how well it works compared to current treatments.

Transplant Rejection1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyInfectious DiseasesInternal MedicineOncology

Chemotherapy Dose Adjustment for DPD-Deficient Gastrointestinal Cancer Patients

We are studying how to safely adjust chemotherapy doses for patients with gastrointestinal cancers who lack a specific liver enzyme. This may help reduce severe side effects during treatment.

Gastrointestinal Cancer Patients Starting Chemotherapy>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Chronic Low Back Pain: Stem Cell Injection Study

We are investigating whether injecting stem cells into the spine can help reduce pain and improve function in people with chronic low back pain from degenerative disc disease. This trial is for those who haven't responded to traditional treatments.

Degenerative Disc Disease>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Metastatic Pancreatic Cancer: Dostarlimab with mFOLFIRINOX

We are studying a new treatment combining Dostarlimab, vitamin D3, and standard chemotherapy for patients with untreated metastatic pancreatic cancer. The goal is to see if this combination can effectively fight the cancer and assess its safety.

Metastatic Pancreatic Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Inebilizumab for Children with Neuromyelitis Optica Spectrum Disorder

We are studying how the medication inebilizumab affects children and adolescents with NMOSD. The trial will help us learn about its safety and how it impacts their health and daily life.

Neuromyelitis Optica Spectrum Disorder1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Mucopolysaccharidosis IIIA: Gene Therapy Study

We are testing a new gene therapy called UX111 for individuals with Mucopolysaccharidosis IIIA. The goal is to see if it is safe and effective in treating this condition.

Mucopolysaccharidosis III>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurologyPediatrics

Venous Malformations: Enalapril Study

We are testing the medication enalapril in adults with painful venous malformations to see if it helps reduce pain and improve quality of life. We will also look at any changes in the size of the malformations.

Venous Malformation>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

Tocilizumab for Painful Chronic Pancreatitis

We are studying whether tocilizumab can help reduce pain and improve quality of life for people with chronic pancreatitis. The trial will compare its effects to a placebo treatment.

Chronic Pancreatitis3-6 monthsEfficacy phase (II)Standard MedicinesGastroenterologyInternal Medicine

Stage IV Non-Small Cell Lung Cancer: Immunotherapy and Radiotherapy Study

We are exploring whether combining immunotherapy with extensive radiotherapy is safe and effective for patients with stage IV non-small cell lung cancer. This study will help us understand the treatment's impact on health and quality of life.

Non-small Cell Lung Cancer (Stage IV)>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Metastatic Colorectal Cancer: Personalized Treatment Study

We are investigating whether tailored therapies based on genetic testing can improve treatment outcomes for patients with metastatic colorectal cancer. This study aims to assess the effectiveness and safety of these new treatment options.

Metastatic Colorectal CancerEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Breast Cancer: Personalized Treatment with Capivasertib

We are studying a new treatment combining capivasertib with letrozole for women with hormone receptor positive breast cancer. This trial aims to see if this approach improves survival compared to standard treatment.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

ARDS Treatment: Recombinant Human Plasma Gelsolin

We are studying whether intravenous recombinant human plasma gelsolin is safe and may help patients with moderate-to-severe ARDS caused by pneumonia or infections. This trial compares it to a placebo alongside standard care.

Acute Respiratory Distress Syndrome (ARDS)≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesPulmonology

Cerebral Amyloid Angiopathy: ALN-APP Treatment Study

We are studying a new treatment called ALN-APP for patients with Cerebral Amyloid Angiopathy. The goal is to see if it helps reduce new brain bleeding and improve overall brain health.

Cerebral Amyloid Angiopathy1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Systemic Lupus Erythematosus: Rapcabtagene Autoleucel Study

We are studying a new treatment for people with difficult-to-treat kidney disease caused by systemic lupus erythematosus. The goal is to see if it works better than standard care in improving kidney health.

Systemic Lupus Erythematosus with Lupus Nephritis1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNephrologyRheumatology